Can Public Transit Support Local and Federal Climate Plans?

The march toward cleaner cities continues at the local and federal level – but there are many roadblocks still ahead.

Key questions surround the role of public transit in the overall effort to lessen the environmental impact of the ways in which we get around. Can public transportation do its part to support climate-friendly strategies? And more importantly, will local governments maximize public transit for their goals, or leave it behind?

To discuss, Voice of B2B Daniel Litwin invited railway engineer and writer Gareth Dennis onto this episode of MarketScale TV.

The conversation surrounding this issue has heightened with the news that Massachusetts has invested in expanding the sale of electric vehicles as part of its push for cleaner transportation as opposed to encouraging more public transit use or overhauling public transportation options.

So, does that mean more cities and regions will follow suit? Where do public transit use and evolution fall in the quest for cleaner transportation options? The duo discussed.

“Electric personal vehicles, private vehicles, represent quite a sizable change in vehicle operation,” Dennis said. “The [electrical] infrastructure might not be there to support that shift from fossil fuel-burning vehicles with internal combustion engines to electric vehicles. There are some challenges, there.

“Both electric vehicles and public transport require physical infrastructure changes. … The wider picture is whether it’s a good idea for personal, private electric vehicles to be the way forward.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More
Immuno-Oncology
Shaping the Future of Cancer Care Through Immuno-Oncology
April 19, 2025

In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed…

Read More